Myriad Submits a Bid to Study New Cancer Drug
Posted on: Friday, 10 December 2004, 15:00 CST
Salt Lake-based Myriad Genetics Inc. has submitted an investigational new drug application to the U.S. Food and Drug Administration to begin a Phase I clinical study of a new cancer drug.
The study is designed to evaluate the safety and "pharmacokinetic profile" of the drug in patients with advanced solid tumors, in an escalating dose regimen, Myriad said in a statement Thursday.
In preclinical testing, Myriad stated the drug has been equally active against multiple drug-resistant cancers as with susceptible tumors, unlike many of the current options in cancer chemotherapy.
Source: Deseret News (Salt Lake City)
Related Articles
- EpiCept Reports on Cancer Compound Trial Developments
- EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
- Myriad Genetics Completes Enrollment in Second Phase 3 Clinical Trial of Flurizan(TM) in Alzheimer's Disease
- Myriad Reports Positive Results for Alzheimer's Drug
- Positive Trial for Myriad Alzheimer's Drug
- Myriad Genetics Advances Antithrombin Drug Development
- Myriad Tests Alzheimer's Drug
- Alzheimer's Drug Fails Key Test, Myriad Says
- Myriad Genetics Submits IND on MPC-6827 Cancer Drug
Rating: 3.5 / 5 (11 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds